臨床試驗
Under the development code ZX008, the pharmaceutical company Zogenix is studying fenfluramine's potential to treat seizures. Clinical trials have studied the use of fenfluramine in patients with Dravet syndrome. Results of a Phase III clinical trial showed a 64% reduction in seizures.